Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review

British Journal of Pharmacology

Volumn 172, Issue 3, 2015, Pages 737-753

  McPartland, John M ^a   Duncan, Marnie ^a   Di Marzo, Vincenzo ^b   Pertwee, Roger G ^c  

^a Porton Down Science Park   (United Kingdom)

^b CNR   (Italy)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; DELTA9 TETRAHYDROCANNABIVARIN; ENDOCANNABINOID; RIMONABANT; UNCLASSIFIED DRUG; CANNABINOID RECEPTOR AFFECTING AGENT; DRONABINOL; TETRAHYDROCANNABIVARIN 9;

BINDING AFFINITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TISSUE LEVEL; HUMAN; LIGAND BINDING; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; NONHUMAN; PROTEIN FUNCTION; RECEPTOR BLOCKING; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM;

ANIMALS; CANNABIDIOL; CANNABINOID RECEPTOR MODULATORS; DRONABINOL; ENDOCANNABINOIDS; HUMANS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 84920829439     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12944     Document Type: Review

References (123)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Ion Channels. Br J Pharmacol 170: 1607-1651.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013d). The Concise Guide to PHARMACOLOGY 2013/14: Transporters. Br J Pharmacol 170: 1706-1796.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA et al. (2013e). The Concise Guide to PHARMACOLOGY 2013/14: Ligand-Gated Ion Channels. Br J Pharmacol 170: 1582-1606.
6. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013f). The Concise Guide to PHARMACOLOGY 2013/14: Nuclear Hormone Receptors. Br J Pharmacol 170: 1652-1675.
7. Bayewitch M, Rhee MH, Avidor-Reiss T, Breuer A, Mechoulam R, Vogel Z (1996). (-)-delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem 271: 9902-9905.
8. Bermudez-Silva FJ, Viveros MP, McPartland JM, Rodriguez de Fonseca F (2010). The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning? Pharmacol Biochem Behav 95: 375-382.
9. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T et al. (2010). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35: 764-774.
10. 9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br J Pharmacol 160: 677-687.
11. Booker L, Naidu PS, Razdan RK, Mahadevan A, Lichtman AH (2009). Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception. Drug Alcohol Depend 105: 42-47.
12. Browne RG, Weissman A (1981). Discriminative stimulus properties of delta 9-tetrahydrocannabinol: mechanistic studies. J Clin Pharmacol 21: 227S-234S.
13. Campos AC, Guimaraes FS (2008). Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology (Berl) 199: 223-230.
14. Campos AC, Guimaraes FS (2009). Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 33: 1517-1521.
15. Campos AC, de Paula Soares V, Carvalho MC, Ferreira FR, Vicente MA, Brandão ML et al. (2013). Involvement of serotonin-mediated neurotransmission in the dorsal periaqueductal gray matter on cannabidiol chronic effects in panic-like responses in rats. Psychopharmacology (Berl) 226: 13-24.
16. Campos AC, Ortega Z, Palazuelos J, Fogac¸a MV, Aguiar DC, Díaz-Alonso J et al. (2013). The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. Int J Neuropsychopharmacol 16: 1407-1419.
17. Castillo A, Tolón MR, Fernández-Ruiz J, Romero J, Martinez-Orgado J (2010). The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. Neurobiol Dis 37: 434-440.
18. Cawthorne M, Stott C, Wright S, Guy G, Zaibi M, Wargent E (2008). The metabolic effects of tetrahydrocannabivarin (THCV) and cannabidiol (CBD). Proceedings of the 18th Annual Symposium on the Cannabinoids. International Cannabinoid Research Society, Burlington, VT, p. 42.
19. Clapper JR, Moreno-Sanz G, Russo R, Guijarro A, Vacondio F, Duranti A et al. (2010). Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci 13: 1265-1270.
20. Cocchetto DM, Cook LF, Cato AE (1981). A critical review of the safety and antiemetic efficacy of delta-9-tetrahydrocannabinol. Drug Intell Clin Pharm 15: 867-875.
21. Comelli F, Giagnoni G, Bettoni I, Colleoni M, Costa B (2008). Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved. Phytother Res 22: 1017-1024.
22. Costa B, Giagnoni G, Franke C, Trovato AE, Colleoni M (2004). Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol 143: 247-250.
23. De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, Petrosino S et al. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 163: 1479-1494.
24. 9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl) 219: 859-873.
25. Demirakca T, Sartorius A, Ende G, Meyer N, Welzel H, Skopp G et al. (2011). Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol. Drug Alcohol Depend 114: 242-245.
26. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC (1988). Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34: 605-613.
27. Di Marzo V (2008). Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7: 438-455.
28. Di Marzo V (2010). Anandamide serves two masters in the brain. Nat Neurosci 13: 1446-1448.
29. Di Marzo V, Melck D, Bisogno T, De Petrocellis L (1998). Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 21: 521-528.
30. Di Marzo V, De Petrocellis L, Fezza F, Ligresti A, Bisogno T (2002). Anandamide receptors. Prostaglandins Leukot Essent Fatty Acids 66: 377-391.
31. El Yacoubi M, Ledent C, Ménard JF, Parmentier M, Costentin J, Vaugeois JM (2000). The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors. Br J Pharmacol 129: 1465-1473.
32. Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S et al. (2013). Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 27: 19-27.
33. Fadda P, Robinson L, Fratta W, Pertwee RG, Riedel G (2004). Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats. Neuropharmacology 47: 1170-1179.
34. Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R et al. (2009). Distinct effects of delta-9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 66: 95-105.
35. Gaoni Y, Mechoulam R (1964). Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 86: 1646-1647.
36. 9-THCV in animal models of Parkinson's disease. Br J Pharmacol 163: 1495-1506.
37. Gill EW, Paton WDM, Pertwee RG (1970). Preliminary experiments on the chemistry and pharmacology of Cannabis. Nature 228: 134-136.
38. Glass GV, McGaw B, Smith ML (1981) Meta-Analysis in Social Research. SAGE Publications: Beverly Hills, CA.
39. Gomes FV, Resstel LB, Guimarães FS (2011). The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors. Psychopharmacology (Berl) 213: 465-473.
40. Gomes FV, Del Bel EA, Guimarães FS (2013). Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice. Prog Neuropsychopharmacol Biol Psychiatry 46: 43-47.
41. Grinspoon L, Bakalar JB (1997) Marihuana, the Forbidden Medicine. Yale University Press: New Haven, CT.
42. Guy GW, Stott CG (2005) The development of Sativex - a natural cannabis-based medicine. In: Mechoulam R (ed.). Cannabinoids as Therapeutics. Birkhäuser Verlag: Basel, pp. 231-263.
43. Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998). Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 95: 8268-8273.
44. Hanuš L (2008). Pharmacological and therapeutic secrets of plant and brain (endo)cannabinoids. Med Res Rev 29: 213-271.
45. Hayakawa K, Mishima K, Hazekawa M, Sano K, Irie K, Orito K et al. (2008). Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism. Brain Res 1188: 157-164.
46. Higgins JPT, Green S (2005) Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. John Wiley & Sons: Chichester, UK.
47. 9-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats. Epilepsia 51: 1522-1532.
48. Hollister LE (1973). Cannabidiol and cannabinol in man. Experientia 29: 825-826.
49. Hopkins AL (2008). Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4: 682-690.
50. Howlett AC, Scott DK, Wilken GH (1989). Regulation of adenylate cyclase by cannabinoid drugs. Insights based n thermodynamic studies. Biochem Pharmacol 38: 3297-3304.
51. Ilan AB, Gevins A, Coleman M, ElSohly MA, de Wit H (2005). Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. Behav Pharmacol 16: 487-496.
52. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R (2009). Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30: 515-527.
53. Izzo AA, Zaibi MS, Wargent E, Capasso R, Arbuckle C, Duncan M et al. (2013). The effect of Δ9-tetrahydrocannabivarin on food deprivation-induced food intake and upper gastrointestinal motility: differences from rimonabant. Proceedings of the 7th Conference on Cannabinoids in Medicine. International Association for Cannabis as Medicine, Köln, p. 57.
54. Jamontt JM, Molleman A, Pertwee RG, Parsons ME (2010). The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. Br J Pharmacol 160: 712-723.
55. Järbe TU, Henriksson BG, Ohlin GC (1977). Delta9-THC as a discriminative cue in pigeons: effects of delta8-THC, CBD, and CBN. Arch Int Pharmacodyn Ther 228: 68-72.
56. Jeon YJ, Yang KH, Pulaski JT, Kaminski NE (1996). Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappa B/Rel activation. Mol Pharmacol 50: 334-341.
57. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT (2010). Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 39: 167-179.
58. Jones NA, Glyn SE, Akiyama S, Hill TD, Hill AJ, Weston SE et al. (2012). Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure 21: 344-352.
59. Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA (2011a). Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem 57: 66-75.
60. Karschner EL, Darwin WD, McMahon RP, Liu F, Wright S, Goodwin RS et al. (2011b). Subjective and physiological effects after controlled Sativex and oral THC administration. Clin Pharmacol Ther 89: 400-407.
61. 9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology (Berl) 218: 443-457.
62. Kozak KR, Crews BC, Morrow JD, Wang LH, Ma YH, Weinander R et al. (2002). Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem 277: 44877-44885.
63. Kozela E, Pietr M, Juknat A, Rimmerman N, Levy R, Vogel Z (2010). Cannabinoids delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. J Biol Chem 285: 1616-1626.
64. Lerner TN, Horne EA, Stella N, Kreitzer AC (2010). Endocannabinoid signaling mediates psychomotor activation by adenosine A2A antagonists. J Neurosci 30: 2160-2164.
65. Leweke FM, Schneider U, Radwan M, Schmidt E, Emrich HM (2000). Different effects of nabilone and cannabidiol on binocular depth inversion in man. Pharmacol Biochem Behav 66: 175-181.
66. Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C et al. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2: e94.
67. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC et al. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6: e1000100.
68. Ligresti A, Schiano Moriello A, Starowicz K, Matias I, Pisanti S, De Petrocellis L et al. (2006). Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmcol Exp Ther 318: 1375-1387.
69. Loewe WS, Modell W (1941). The action of chemical components of cannabis extracts. J Pharmacol Exp Ther 72: 27.
70. Long LE, Chesworth R, Huang XF, McGregor IS, Arnold JC, Karl T (2010). A behavioural comparison of acute and chronic D9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol 13: 861-876.
71. Maione S, Piscitelli F, Gatta L, Vita D, De Petrocellis L, Palazzo E et al. (2011). Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. Br J Pharmacol 162: 584-596.
72. Malone DT, Jongejan D, Taylor DA (2009). Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats. Pharmacol Biochem Behav 93: 91-96.
73. Marcu JP, Christian RT, Lau D, Zielinski AJ, Horowitz MP, Lee J et al. (2010). Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol Cancer Ther 9: 180-189.
74. Martire A, Tebano MT, Chiodi V, Ferreira SG, Cunha RA, Köfalvi A et al. (2011). Pre-synaptic adenosine A2A receptors control cannabinoid CB1 receptor-mediated inhibition of striatal glutamatergic neurotransmission. J Neurochem 116: 273-280.
75. May LT, Leach K, Sexton PM, Christopoulous A (2007). Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47: 1-51.
76. McPartland JM, Guy G (2004) The evolution of Cannabis and coevolution with the cannabinoid receptor - a hypothesis. In: Guy G, Robson R, Strong K, Whittle B (eds). The Medicinal Use of Cannabis. Royal Society of Pharmacists: London, pp. 71-102.
77. McPartland JM, Pruitt PL (1999). Side effects of pharmaceuticals not elicited by comparable herbal medicines: the case of tetrahydrocannabinol and marijuana. Altern Ther Health Med 5: 57-62.
78. McPartland JM, Russo EB (2001). Cannabis and cannabis extracts: greater than the sum of their parts? J Cannabis Therapeutics 1: 103-132.
79. McPartland JM, Glass M, Pertwee RG (2007). Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br J Pharmacol 152: 583-593.
80. Mechoulam R, Fride E, Di Marzo V (1998). Endocannabinoids. Eur J Pharmacol 359: 1-18.
81. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanuš LO (2007). Cannabidiol - recent advances. Chem Biodivers 4: 1678-1692.
82. de Meijer EPM, Bagatta M, Carboni A, Crucitti P, Cristiana Moliterni VM, Ranalli P et al. (2003). The inheritance of chemical phenotype in Cannabis sativa L. Genetics 163: 335-346.
83. Morgan CJ, Curran HV (2008). Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 192: 306-307.
84. Morgan CJ, Freeman TP, Schafer GL, Curran HV (2010a). Cannabidiol attenuates the appetitive effects of delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology 35: 1879-1885.
85. Morgan CJ, Schafer G, Freeman TP, Curran HV (2010b). Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatry 197: 285-290.
86. Nicholson AN, Turner C, Stone BM, Robson PJ (2004). Effect of delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol 24: 305-313.
87. Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S et al. (2004). Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia 59: 440-452.
88. O'Brien LD, Wills KL, Segsworth B, Dashney B, Rock EM, Limebeer CL et al. (2013). Effect of chronic exposure to rimonabant and phytocannabinoids on anxiety-like behavior and saccharin palatability. Pharmacol Biochem Behav 103: 597-602.
89. Palazzo E, de Novellis V, Petrosino S, Marabese I, Vita D, Giordano C et al. (2006). Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system. Eur J Neurosci 24: 2011-2020.
90. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-1106.
91. Pertwee RG (2004) The pharmacology and therapeutic potential of cannabidiol. In: Di Marzo V (ed.). Cannabinoids. Kluwer Academic/Plenum Publishers: New York, pp. 32-83.
92. Pertwee RG (2005). The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J 7: E625-E654.
93. Pertwee RG (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153: 199-215.
94. 9-tetrahydrocannabivarin in mice in vivo. Br J Pharmacol 150: 586-594.
95. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR et al. (2010). International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 62: 588-631.
96. Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC (1998). Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63: PL1-PL6.
97. Qin N, Neeper MP, Liu Y, Hutchinson TL, Lubin ML, Flores CM (2008). TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neuroscience 28: 6231-6238.
98. Reed GF, Lynn F, Meade BD (2002). Use of coefficient of variation in assessing variability of quantitative assays. Clin Diagn Lab Immunol 9: 1235-1239.
99. Rhee MH, Vogel Z, Barg J, Bayewitch M, Levy R, Hanus L et al. (1997). Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J Med Chem 40: 3228-3233.
100. Riedel G, Fadda P, McKillop-Smith S, Pertwee RG, Platt B, Robinson L (2009). Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Br J Pharmacol 156: 1154-1166.
101. 9-tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats. Br J Pharmacol 170: 671-678.
102. Roser P, Gallinat J, Weinberg G, Juckel G, Gorynia I, Stadelmann AM (2009). Psychomotor performance in relation to acute oral administration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects. Eur Arch Psychiatry Clin Neurosci 259: 284-292.
103. Russo E, Guy GW (2006). A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66: 234-246.
104. Russo EB (2004). Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett 25: 31-39.
105. Russo EB (2011). Taming THC: potential cannabis synergy and phytocannabinoid-pterpenoid entourage effects. Br J Pharmacol 163: 1344-1364.
106. Sagredo O, Pazos MR, Satta V, Ramos JA, Pertwee RG, Fernández-Ruiz J (2011). Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease. J Neurosci Res 89: 1509-1518.
107. Savinainen JR, Saario SM, Niemi R, Järvinen T, Laitinen JT (2003). An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors. Br J Pharmacol 140: 1451-1459.
108. Schubart CD, Sommer IE, van Gastel WA, Goetgebuer RL, Kahn RS, Boks MP (2011). Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res 130: 216-221.
109. Shafaroodi H, Samini M, Moezi L, Homayoun H, Sadeghipour H, Tavakoli S et al. (2004). The interaction of cannabinoids and opioids on pentylenetetrazole-induced seizure threshold in mice. Neuropharmacology 47: 390-400.
110. Stott CG, White L, Wright S, Wilbraham D, Guy GW (2013). A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. Eur J Clin Pharmacol 69: 1135-1147.
111. Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W et al. (2006). Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 24: 3394-3400.
112. Vann RE, Gamage TF, Warner JA, Marshall EM, Taylor NL, Martin BR et al. (2008). Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol. Drug Alcohol Depend 94: 191-198.
113. Varvel SA, Wiley JL, Yang R, Bridgen DT, Long K, Lichtman AH et al. (2006). Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology (Berl) 186: 226-234.
114. Wade DT, Robson P, House H, Makela P, Aram J (2003). A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 17: 21-29.
115. Wallace MJ, Blair RE, Falenski KW, Martin BR, DeLorenzo RJ (2003). The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther 307: 129-137.
116. Wargent ET, Zaibi MS, Silvestri C, Hislop DC, Stocker CJ, Stott CG et al. (2013). The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. Nutr Diabetes 3: e68.
117. Wilkinson JD, Whalley BJ, Baker D, Pryce G, Constanti A, Gibbons S et al. (2005). Medicinal cannabis: is delta9-tetrahydrocannabinol necessary for all its effects? J Pharm Pharmacol 55: 1687-1694.
118. Williamson EM (2001). Synergy and other interactions in phytomedicines. Phytomedicine 8: 401-409.
119. Wolf SA, Bick-Sander A, Fabel K, Leal-Galicia P, Tauber S, Ramirez-Rodriguez G et al. (2010). Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis. Cell Commun Signal 8: 12.
120. Xiong W, Cheng K, Cui T, Godlewski G, Rice KC, Xu Y et al. (2011). Cannabinoid potentiation of glycine receptors contributes to cannabis-induced analgesia. Nat Chem Biol 7: 296-303.
121. Zijicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A et al. (2003). Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362: 1517-1526.
122. Zuardi AW (2008). Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 30: 271-280.
123. Zuardi AW, Finkelfarb E, Bueno OF, Musty RE, Karniol IG (1981). Characteristics of the stimulus produced by the mixture of cannabidiol with delta 9-tetrahydrocannabinol. Arch Int Pharmacodyn Ther 249: 137-146.